Clinical trial · Interventional
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Merrimack Pharmaceuticals Inc.)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Based on the preliminary results seen during interim analysis, which were confirmed in the final analysis, the Sponsor terminated the study
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Heregulin | — | UNRESOLVED | — |
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| MM-121 | Drug | Seribantumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm A: Experimental Arm
- description
- MM-121 in combination with Docetaxel
- interventionNames
- Drug: MM-121
- Drug: Docetaxel
- type
- ACTIVE_COMPARATOR
- label
- Arm B: Comparator Arm
- description
- Docetaxel alone
- interventionNames
- Drug: Docetaxel
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- Randomization until progression of disease or death due to any cause within 3 years,11 months (the study terminated prematurely)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent * Not received more than 2 prior systemic therapies- one of which must have been a platinum based regimen- for primary or recurrent disease * Tissue submitted for HRG-biomarker testing * ECOG performance status (PS) of 0 or 1 Exclusion Criteria: * Known ALK mutation * Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene * Received \>2 prior systemic anti-cancer drug regimen for locally advanced disease * Prior treatment with an anti-ErbB3 antibody * CTCAE grade 3 or higher peripheral neuropathy * Symptomatic CNS metastases or CNS metastases requiring steroids * Any other active malignancy requiring systemic therapy * Clinically significant cardiac disease
References
Publications (1)
- DERIVEDSequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11. PMID 30975923